Data updated: Mar 10, 2026
GANZYK-RTU
GANCICLOVIR
Approved 2017-02-17
1
Indication
--
Phase 3 Trials
9
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2017-02-17
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
GANZYK-RTU Approval History
Loading approval history...
What GANZYK-RTU Treats
1 FDA approvalsOriginally approved for its first indication in 2017 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
GANZYK-RTU FDA Label Details
ProGANZYK-RTU Patents & Exclusivity
Latest Patent: Sep 2034
Patents (1 active)
US9486530
Expires Sep 2, 2034
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.